2,530 results on '"Baccarani, M."'
Search Results
52. The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
53. Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury
54. Dual tyrosine kinase inhibitors in chronic myeloid leukemia
55. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia
56. Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML
57. A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia
58. Nuclear factor-erythroid 2 (NF-E2) expression in normal and malignant megakaryocytopoiesis
59. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
60. Dendritic cell recovery after autologous stem cell transplantation
61. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia
62. Use of anti-BDCA-2 antibody for detection of dendritic cells type-2 (DC2) in allogeneic hematopoietic stem cell transplantation
63. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
64. Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study
65. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
66. Initial treatment for patients with chronic myeloid leukemia
67. Posttransplant Lymphoproliferative Disorders in Liver Transplanted Patients: A Report of Four Cases
68. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy
69. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
70. Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease
71. Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
72. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
73. Autologous bone marrow transplantation in non-Hodgkin’s lymphoma patients: effect of a brief course of G-CSF on harvest and recovery
74. Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia
75. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)
76. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
77. Nilotinib exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML): 1124402
78. Hypoxic bone marrow stromal cells create a pro-survival niche for breast cancer stem cells: P1004
79. CD133+ pluripotent stem cells for the treatment of chronic liver failure: P1001
80. Genetic variability at loci controlling glutathion homeostasis affects transplant-related mortality and overall survival in patients receiving an allogeneic HSCT after a busulfanbased conditioning regimen: P966
81. Prognostic factors and outcomes of adults with acute lymphoblastic leukaemia who relapse after allogeneic haematopoietic cell transplantation. An analysis by the Acute Leukaemia Working Party of the EBMT: P912
82. Intrabone cord blood transplant: preliminary results from a prospective phase II study: P531
83. Punctal occlusion for the treatment of severe dry eyes in patients after allogeneic stem cell transplantation: a non-interventional prospective study of the complications subcommittee of the Chronic Leukaemia Working party of the EBMT: 247
84. Effect of prior therapy with nilotinib or dasatinib on the outcome after allogeneic stem cell transplantation for patients with chronic myeloid leukaemia: a noninterventional prospective study by the CML subcommittee of the Chronic Leukaemia Working Party: 242
85. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
86. PI-PLCβ-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes
87. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia
88. Autologous stem cell transplantation for aggressive non-Hodgkin’s lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index
89. Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study: 101
90. Phase I-II trial of adoptive immunotherapy with haploidentical KIR ligand-mismatched natural killer cells in high-risk acute myeloblastic leukaemia patients: O400
91. IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report: O133
92. Less extensive chronic GvHD with PBSC and ATG for sibling transplants without increase in TRM or relapse: O142
93. pH-positive acute lymphoblastic leukaemia is characterised by recurrent copy number anomalies in genes regulating the cell cycle and B-cell differentiation: O138
94. Pathways Shared by t(4;14) and D13 positive MM Patients Impact Response to Velcade/Thalidomide/Dexamethasone: B497
95. Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM: A451
96. Thalidomide/Dexamethasone Induction Therapy in Newly Diagnosed Myeloma Patients with Renal Failure: A174
97. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase
98. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis
99. The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin’s lymphoma
100. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on ‘in vitro’ growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.